NLRP3 and Hepatic fibrosis: The latest research shows that TREM2+LAMs can inhibit NLRP3 activation and pro-inflammatory cytokine secretion, then degrade the ECM in the liver, thereby accelerating the regression of liver fibrosis (104) (Figure 3).